Beam Locks a September BEAM-302 Catalyst

Company Beam Therapeutics Event Type Clinical Catalyst Announcement (Phase 1/2 Data Presentation Scheduled) Modality In Vivo Adenine Base Editing (LNP-Delivered) Asset BEAM-302 Target SERPINA1 (PiZ / E342K) Disease Area Alpha-1 Antitrypsin Deficiency Summary Beam Therapeutics announced that updated Phase 1/2 BEAM-302 data will be presented…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Weekly Market Insight

Nurix + Roche; Global BTK Degrader Collaboration
ARPA-H Commits $160M to Personalized Gene Editing
Merck – $1B Google AI Deal
Scancell Funds a Phase 3 Melanoma Bet